HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This study examines the impact of fosamprenavir as part of an ART on virological,
immunological and clinical parameters of genotype 1 HCV infection in HIV co-infected
subjects. Fosamprenavir could have a direct or immune-mediated activity against HCV. If this
is shown to be true, changes in HCV viral load or biological characteristics could be
demonstrated.